IP Verse

Merck Sharp & Dohme Corp. opposition analysis

COMPANY ANALYSIS

Latest oppositions filed by Merck Sharp & Dohme Corp.

Patent Number:
EP2863895
Title:
Tablet Formulation Comprising A Peptide And A Delivery Agent
Applicant:
NOVO NORDISK A/S
Opposition Date:
Jan 13, 2022
Patent Number:
EP3096785
Title:
Immunogenic Compositions Comprising Conjugated Capsular Saccharide Antigens And Uses Thereof
Applicant:
PFIZER INC.
Opposition Date:
Jun 4, 2021
Patent Number:
EP3002298
Title:
Anti-Factor Xi Monoclonal Antibodies And Methods Of Use Thereof
Applicant:
OREGON HEALTH & SCIENCE UNIVERSITY
Opposition Date:
Apr 8, 2020
Patent Number:
EP3326641
Title:
Rna Containing Composition For Treatment Of Tumor Diseases
Applicant:
CUREVAC AG
Opposition Date:
Mar 24, 2020
Patent Number:
EP2676679
Title:
Formulations Which Stabilize And Inhibit Precipitation Of Immunogenic Compositions
Applicant:
WYETH LLC
Opposition Date:
Oct 2, 2019
Patent Number:
EP2586788
Title:
Prevention Of Disulfide Bond Reduction During Recombinant Production Of Polypeptides
Applicant:
GENENTECH, INC.
Opposition Date:
Aug 29, 2018
Patent Number:
EP2815762
Title:
Conjugation Process Of Bacterial Polysaccharides To Carrier Proteins
Applicant:
GLAXOSMITHKLINE BIOLOGICALS S.A.
Opposition Date:
Feb 26, 2018
Patent Number:
EP1234031
Title:
B7-H1, A Novel Immunoregulatory Molecule
Applicant:
MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH
Opposition Date:
Dec 15, 2017
Patent Number:
EP2496700
Title:
Nucleic Acid-Containing Lipid Particles And Related Methods
Applicant:
THE UNIVERSITY OF BRITISH COLUMBIA
Opposition Date:
Dec 1, 2017

Latest patents of Merck Sharp & Dohme Corp. opposed by its competitors

Patent:
EP3283882
Grant Date:
Oct 16, 2024
Title:
Blood-Based Biomarkers Of Tumor Sensitivity To Pd-1 Antagonists
Oppositions:
1
Patent:
EP1841493
Grant Date:
May 29, 2024
Title:
Applicator For Inserting An Implant
Oppositions:
1
Patent:
EP3265122
Grant Date:
May 4, 2022
Title:
Combination Of A Pd-1 Antagonist And Eribulin For Treating Cancer
Oppositions:
4
Patent:
EP2981821
Grant Date:
Nov 3, 2021
Title:
Immunohistochemical Assay For Detecting Expression Of Programmed Death Ligand 1 (Pd-L1) In Tumor Tissue
Oppositions:
1
Patent:
EP2931301
Grant Date:
Sep 15, 2021
Title:
Process For Purifying Insulin And Analogues Thereof
Oppositions:
1
Patent:
EP3498734
Grant Date:
Sep 1, 2021
Title:
Combination Of A Pd-1 Antagonist And A Vegfr Inhibitor For Treating Cancer
Oppositions:
7
Patent:
EP3391890
Grant Date:
Aug 25, 2021
Title:
Posaconazole Intravenous Solution Formulations Stabilized By Substituted Beta-Cyclodextrin
Oppositions:
4
Patent:
EP2970916
Grant Date:
Apr 14, 2021
Title:
Adapted Lepidopteran Insect Cells For The Production Of Recombinant Proteins
Oppositions:
2
Patent:
EP3036256
Grant Date:
Oct 28, 2020
Title:
Modulation Of Tumor Immunity
Oppositions:
2
Patent:
EP2935329
Grant Date:
Sep 16, 2020
Title:
Antibodies That Bind To Human Programmed Death Ligand 1 (Pd-L1)
Oppositions:
2

Competitors of Merck Sharp & Dohme Corp.

PAJARO LIMITED

KONIG SZYNKA TILMANN VON RENESSE

GENERICS (U.K.) LIMITED

Want to track Merck Sharp & Dohme Corp.?

Feel free to send us a message here and we will get back to you